Results 181 to 190 of about 148,802 (383)

Antireflux myoplasty: Endoscopic myoplasty with bilateral sling fiber plication for refractory gastroesophageal reflux disease. [PDF]

DEN Open
Abstract Endoscopic antireflux therapy is a novel endoscopic treatment for refractory gastroesophageal reflux disease. We developed antireflux myoplasty (AR‐MP), a modified version of antireflux mucoplasty (ARM‐P), in which exposed bilateral sling fibers are sutured directly via endoscopic hand‐suturing.
Shiwaku H, Shiwaku A, Irie H, Akasaki T, Sato S, Koreeda N, Shirakabe K, Yamauchi K, Inoue H, Hasegawa S.   +9 more
europepmc   +2 more sources

A Physiologic Approach to Laparoscopic Fundoplication for Gastroesophageal Reflux Disease

, 1996
John G. Hunter, T. L. Trus, Gene D. Branum, J. Patrick Waring, William C. Wood   +4 more
openalex   +2 more sources

Certain unsolved questions of pathogenetic interrelation between gastroesophageal reflux disease and chronic forms of ischemic heart disease (review of the references) [PDF]

, 2016
The article deals with correlation links of developmental mechanisms and progressing of gastroesophageal reflux disease in patients with chronic forms of ischemic heart disease.
Drozd, V.Y., Hryniuk, О.Е., Khukhlina, O.S., Mandryk, O.E.   +3 more
core  

Peroral endoscopic myotomy in spastic esophageal disorders: Clinical outcomes and optimal approaches

Digestive Endoscopy, EarlyView.
Objectives The efficacy and safety of peroral endoscopic myotomy (POEM) for spastic esophageal disorders (SED), including type III achalasia, distal esophageal spasm (DES), and jackhammer esophagus (JE), remain uncertain due to its rarity. This study aimed to evaluate the clinical outcomes and optimal strategies for managing SED.
Tetsuya Tatsuta, Haruhiro Inoue, Yuto Shimamura, Miyuki Iwasaki, Kei Ushikubo, Kazuki Yamamoto, Yohei Nishikawa, Hidenori Tanaka, Ippei Tanaka, Satoshi Abiko, Mayo Tanabe, Kazuya Sumi, Manabu Onimaru, Boldbaatar Gantuya, Hirotake Sakuraba, Shinsaku Fukuda   +15 more
wiley   +1 more source

MODERN ASPECTS OF THE COMBINED PATHOLOGY: BRONCHIAL ASTHMA AND DISEASES OF THE UPPER GASTROINTESTINAL TRACT SEGMENTS AMONG CHILDREN

Педиатрическая фармакология, 2008
The article is devoted to the combined pathology in childhood, namely a combination of bronchial asthma and gastroesophageal reflux disease. The authors highlighted the key theories of the disease etiopathogenesis under alternating environmental ...
S.K. Arshba
doaj   +2 more sources

Inflammation and Specialized Intestinal Metaplasia of Cardiac Mucosa Is a Manifestation of Gastroesophageal Reflux Disease

, 1997
Stefan Öberg, J. H. Peters, Thomas Demeester, Para Chandrasoma, J. A. Hagen, Adrian P. Ireland, Manfred Ritter, Rodney J. Mason, Peter F. Crookes, Cedric G. Bremner   +9 more
openalex   +2 more sources

The Treatment of Gastroesophageal Reflux Disease With Laparoscopic Nissen Fundoplication

, 1998
Jeffrey H. Peters, Tom R. DeMeester, Peter F. Crookes, Stefan Öberg, Michaela de Vos Shoop, Jeffrey A. Hagen, Cedric G. Bremner   +6 more
openalex   +2 more sources

The Pediatric Screening–Priority Evaluation Dysphagia: Validation of a new tool for screening swallowing disorders in infants and children

Developmental Medicine &Child Neurology, EarlyView.
The Pediatric Screening‐Priority Evaluation Dysphagia (PS‐PED) is a novel, non‐invasive, 14‐item screening tool designed to identify swallowing disorders in children. It encompasses three key domains: clinical history, health status, and feeding condition.
Antonella Cerchiari, Giorgia Biondo, Fausto Maria Fassari, Francesca Pizza, Carolina Giordani, Martina Falbo, Gessica Della Bella, Massimiliano Raponi, Marco Tofani   +8 more
wiley   +1 more source

Update on Gastroesophageal Reflux and Respiratory Disease in Children [PDF]

, 2000
Susan R. Orenstein
openalex   +1 more source

Efficacy and safety of danuglipron (PF‐06882961) in adults with obesity: A randomized, placebo‐controlled, dose‐ranging phase 2b study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This randomized, double‐blind, placebo‐controlled Phase 2b study aimed to assess the efficacy, safety, and tolerability of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in adults with obesity. Materials and Methods Eligible participants (aged 18–75 years; with obesity, without diabetes)
Clare Buckeridge, Sonia Cobain, Harold E. Bays, Osamu Matsuoka, Yasushi Fukushima, Patricia Halstead, Nikolaos Tsamandouras, Nicole Sherry, Donal N. Gorman, Aditi R. Saxena   +9 more
wiley   +1 more source